Prostatype Genomics
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Prostatype Genomics publishes Annual Report for 2025
Prostatype Genomics AB today publishes the Annual Report for the financial year of 2025. The translated Annual Report is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com
Please note that the English version is a translation of the Swedish original.
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
e-mail: fredrik.rickman@prostatypegenomics.com
Certified Adviser
Tapper Partners AB
Telephone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se
About Prostatype Genomics AB
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.
| Datum | 2026-06-01, kl 10:45 |
| Källa | MFN |